Certolizumab is a therapeutic monoclonal antibody, prescribed for Crohn's disease and rheumatoid arthritis. The risk or severity of adverse effects can be increased when Certolizumab pegol is combined ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Please provide your email address to receive an email when new articles are posted on . Certolizumab pegol may be safely reduced in patients across the axial spondyloarthritis spectrum who have ...

- New Cimzia® data, with sites in the US, demonstrate safety and efficacy, increased participation in social activities for adult RA patients ATLANTA, June 16 ...

Review the side-effects of Certolizumab as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

The US Food and Drug Administration (FDA) has approved the tumor necrosis factor (TNF) inhibitor certolizumab pegol (Cimzia, UCB Pharma) for the treatment of adults with active psoriatic arthritis ...

No clinically meaningful disease worsening among women with well-controlled RA, juvenile arthritis. To better understand the real-world prescribing patterns of certolizumab, researchers collected data ...

The efficacy and safety of a new tumor necrosis factor inhibitor, certolizumab pegol, in active rheumatoid arthritis has now been assessed in three phase III, multicenter, randomized, double-blind, ...

June 8, 2012 (Berlin, Germany) — Certolizumab pegol (Cimzia, UCB Pharma), a tumor necrosis factor (TNF) inhibitor approved by the US Food and Drug Administration for the treatment of rheumatoid ...

The appraisal committee reviewed the data available on the clinical and cost effectiveness of certolizumab pegol and secukinumab, having considered evidence on the nature of psoriatic arthritis and ...

The appraisal committee (section 6) considered evidence submitted by UCB Pharma and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the ...